Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WCCT Global announces involvement in H1N1 oral vaccine development
The study was first presented to the scientific community on October 14, 2014 at the World Vaccine Congress in Brussels, Belgium by Vaxart. WCCT Global conducted this phase
The study was first presented to the scientific community on October 14, 2014 at the World Vaccine Congress in Brussels, Belgium by Vaxart. WCCT Global conducted this phase
The randomized, double-blind, placebo-controlled study, known as "EASE LID 3," is planned to enroll approximately 70 patients with LID. The 13-week study will include an estimated 35 sites
Fleet’s management team, along with several additional investors, will hold minority stakes alongside Gryphon. Fleet Laboratories, headquartered in Lynchburg, VA and family-owned since its founding in 1869, is
Americans catch an estimated 1 billion colds annually. During cold and flu season, the Centers for Disease Control and Prevention estimates that as many as 20 percent of
Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition. Kabiven was approved by the U.S. Food
This finding is the culmination of more than 10 years of work by more than a dozen scientists and clinicians in the research team in Sarasota. Alzheimer’s has
The U.S. Food and Drug Administration (FDA) has approved Octagam10% for the treatment of adults with chronic Immune Thrombocytopenic Purpura (ITP), a platelet disorder that can result in
Over the past seven months, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana’s
XTEN is Amunix’s proprietary protein-based polymer that mimics the biophysical properties of PEG and is used to extend the half-life of genetically fused therapeutic proteins and peptides. "We
While BDSI plans to pursue an indication for the maintenance treatment of opioid dependence, the company has also secured the rights and plans to develop a product for